Epidermal growth factor receptor inhibitors in the treatment of nonmelanoma skin cancers

Dermatologic Surgery

Volumn 37, Issue 9, 2011, Pages 1199-1209

  Khan, Misbah H ^a,b   Alam, Murad ^a   Yoo, Simon ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CANERTINIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; LAPATINIB; MATUZUMAB; PACLITAXEL; PANITUMUMAB;

ADVANCED CANCER; CARCINOGENESIS; HAIR DISEASE; HEAD AND NECK CARCINOMA; HUMAN; HYPERPIGMENTATION; HYPERTRICHOSIS; LOADING DRUG DOSE; MULTICENTER STUDY (TOPIC); PARONYCHIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; REVIEW; SKIN CANCER; SKIN FISSURE; SQUAMOUS CELL CARCINOMA; TELANGIECTASIA; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; HUMANS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 80955178804     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2011.02038.x     Document Type: Review

References (54)

1. Hanahan D, Weinberg R., The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
2. Baselga J., New technologies in the epidermal growth factor receptor-targeted cancer therapy. Signal 2000; 1: 12-21.
3. Mendelsohn J, Baselga J., Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-99. (Pubitemid 46606324)
4. Ullrich A, Coussens L, Hayflick JS, Dull TJ, et al,. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309: 418-25. (Pubitemid 14102443)
5. Ogiso H, Ishitani R, Nureki O, Fukai S, et al,. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110: 775-87. (Pubitemid 35291060)
6. Wells A., EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-43. (Pubitemid 29248872)
7. Vivanco I, Sawyers CL., The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501. (Pubitemid 37328931)
8. Alroy I, Yarden Y., The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997; 410: 83-6. (Pubitemid 27283389)
9. Burgering BM, Coffer PJ., Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995; 376: 599-602.
10. Nanney LB, Magid M, Stoscheck CM, King LE Jr., Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984; 83: 385-93. (Pubitemid 14024387)
11. Gullick WJ, Hughes CM, Mellon K, Neal DE, et al,. Immunohistochemical detection of the epidermal growth factor receptor in paraffin-embedded human tissues. J Pathol 1991; 164: 285-9.
12. Herbst RS, Shin DM., Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. A new paradigm for cancer therapy. Am Cancer Soc 2002; 94: 1593-611. (Pubitemid 34212655)
13. Brabender J, Danenberg KD, Metzger R, Schneider PM, et al,. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7: 1850-5. (Pubitemid 32994816)
14. Bauknecht T, Gross G, Hagedorn M., Epidermal growth factor receptors in different skin tumors. Dermatologica 1985; 171: 16-20. (Pubitemid 15069675)
15. Liu B, Zhang H, Li S, Chen W, et al,. The expression of c- erbB-1 and c-erbB-2 oncogenes in basal cell carcinoma and squamous cell carcinoma of skin. Chin Med Sci J 1996; 11: 106-9.
16. Groves RW, Allen MH, MacDonald DM., Abnormal expression of epidermal growth factor receptor in cutaneous epithelial tumors. J Cutan Pathol 1992; 19: 66-72.
17. Krahn G, Leiter U, Kaskel P, Udart M, et al,. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer 2001; 37: 251-9. (Pubitemid 32144704)
18. Shimizu T, Izumi H, Oga A, Furumoto H, et al,. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous cell carcinoma of the skin. Dermatology 2001; 202: 203-6. (Pubitemid 32506966)
19. Ciardiello F, Tortora G., EGFR antagonist in cancer treatment. N Engl J Med 2008; 358: 1160-74.
20. Normanno N, Bianco C, De Luca A, Maiello MR, et al,. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003; 10: 1-21. (Pubitemid 36457237)
21. Bianco R, Damiano V, Gelardi T, Daniele G, et al,. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. Curr Pharm Des 2007; 13: 3358-67. (Pubitemid 350201670)
22. Kolch W, Calder M, Gilbert D., When kinases meet mathematics: the systems biology of MAPK signaling. FEBS Lett 2005; 579: 1891-5. (Pubitemid 40342670)
23. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G., Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316-26. (Pubitemid 36687658)
24. Gille J, Swerlick RA, Caughman SW., Transforming growth factor alpha- induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2- dependent DNA binding and transactivation. EMBO J 1997; 16: 750-9. (Pubitemid 27089522)
25. Ahmed N, Kalka K, Mukhtar H., In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy. Oncogene 2001; 20: 2314-7. (Pubitemid 32531289)
26. Malumbres M, Barbacid M., RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-65. (Pubitemid 37328850)
27. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, et al,. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-8. (Pubitemid 46548951)
28. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, et al,. Wild-type BRAF is required to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-12.
29. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, et al,. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Genes Dev 1998; 12: 502-13. (Pubitemid 28101013)
30. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, et al,. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5: 257-65. (Pubitemid 29085177)
31. Thienelt CD, Bunn PA Jr, Hanna N, Rosenberg A, et al,. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. J Clin Oncol 2005; 23: 8786-93. (Pubitemid 46211524)
32. Vega-Villegas E, Awada R, Mesia L, Geoffrois L, et al,. A phase I study of cetuximab in combination with cisplatin or carboplatin and 5-FU in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Proc Am Assoc Cancer Res 2003; 22: 2020.
33. Herbst RS, Arquette M, Shin DM, Dicke K, et al,. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5578-87.
34. Suen JK, Bressler L, Shord SS, Warso M, et al,. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anti-Cancer Drugs 2007; 18: 827-9. (Pubitemid 46975970)
35. Van-Galvan S, Buceta RL, Ma D-L, Fernandez-Chacon C, et al,. Cetuximab induced hypertrichosis of the scalp and eyelashes. J Am Acad Dermatol 2010; 62: 531-2.
36. Arnold AW, Bruckner-Tuderman L, Zuger C, Itin HP., Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology 2009; 219: 80-3.
37. Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, et al,. Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Deut Dermatol Gesellschaft 2008; 6: 1066-9.
38. Xu K, Shu HK., EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1-Sp3 transcription factors in human gliomas. Cancer Res 2007; 67: 6121-9. (Pubitemid 47037492)
39. Yang XD, Jia XC, Corvalan JRF, Wang P, et al,. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23. (Pubitemid 32194591)
40. Weiner LM, Belldegrum AS, Crawford J, Tolcher AW, et al,. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008; 14: 502-8. (Pubitemid 351226119)
41. vanhoefer U, Tewes M, Rojo F, Dirsch O, et al,. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody in patients with advanced solid tumors that express the EGFR. J Clin Oncol 2004; 22: 175-84. (Pubitemid 41095130)
42. Seiden MV, Burris HA, Matulonis U, Hall JB, et al,. A phase II trial of EMD 72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in patients with platinum-resistance ovarian and primary peritoneal malignancies. Gynecol Oncol 2007; 104: 727-31.
43. Ciardiello F, Caputo R, Bianco R, Damiano V, et al,. Antitumor effect of potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa) an epidermal growth factor receptor selective tyrosine kinase inhibitor. Clini Cancer Res 2000; 6: 2053-63. (Pubitemid 30305105)
44. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, et al,. Suppression of epidermal growth factor receptor mitogen activated protein kinase and Pak 1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2003; 2: 345-51.
45. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, et al,. Activating mutations in the epidermal growth receptor underlying responsiveness of non-small lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39. (Pubitemid 38637993)
46. Moyer JD, Barbacci EG, Iwata KK, Arnold L, et al,. Induction of apoptosis and cell cycle arrest by and epidermal growth receptor inhibitor tyrosine kinase. Cancer Res 1997; 57: 4838-48. (Pubitemid 27468992)
47. Akita RW, Sliwkowski MX., Preclinical studies with Erlotinib (Tarceva). Semin Oncol 2003; 30: 15-24. (Pubitemid 36828624)
48. Herbst RS., Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 2003; 30 (Suppl 7): 34-46. (Pubitemid 36828626)
49. Xia W, Liu LH, Ho P, Spector NL., Truncated ErbB2 receptor is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErBb2 kinase inhibitor GW572016. Oncogene 2004; 23: 646-53. (Pubitemid 38241266)
50. Ranson M., Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2004; 90: 2250-5. (Pubitemid 38961885)
51. Thomas SM, Grandis JR., Pharmcokinetics and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004; 30: 225-68.
52. Busam KJ, Capodieci P, Motzer R, Kiehn T, et al,. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-76. (Pubitemid 34204207)
53. Roe E, Muret GM, Marcuello E, Capdevila J, et al,. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006; 55: 429-37. (Pubitemid 44189595)
54. Robert C, Sorai JC, Spatz A, Le Cesne A, et al,. Cutaneous side effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500. (Pubitemid 40903630)